Magnesium sulfate
General
Systematic name	Magnesium sulfate heptahydrate
Other names	Epsom salts bitter salts
Molecular formula	MgSO4·7H2O
Molar mass	120.3 g/mol
Appearance	white crystalline solid
CAS number	*
EINECS number	?
Properties
Density and phase	g/cm3, solid
Solubility in water	25.5 g/100 ml (20 °C)
In ethanol	Slightly soluble (anh.) Insoluble (hydrate)
Melting point	°C decomp.
Structure
Coordination geometry	?
Crystal structure	monoclinic (hydrate)
Safety data
PEL-TWA (OSHA)	—
RTECS number	?
Supplementary data page
Structure & properties	n, εr, etc.
Thermodynamic data	Phase behaviour Solid, liquid, gas
Spectral data	UV, IR, NMR, MS
Related compounds
Other cations	Calcium sulfate Aluminium sulfate
Related compounds
Except where noted otherwise, data are given for materials in their standard state (at 25°C, 100 kPa) Chemical infobox

Magnesium sulfate or Magnesium sulfate heptahydrate or Epsom salt is a chemical compound containing magnesium, with the formula MgSO₄·7H₂O. Magnesium sulfate without water of crystalization MgSO₄ is available as a far less common chemical and drying agent, but typically "magnesium sulfate" refers to the hydrate, and Epsom salt always refers to the hydrate. In medical preparations the hydrate form is used to prepare and label even magnesium sulfate formulas in water solution, because the hydrate crystals, which are not deliquescent, are far more easily weighed and subject to quality control in manufacture.

More on [ Magnesium sulfate ]

CFDA: FDA Latest Computer Systems Warning Letters

WL Issued to Amrex Zetron Inc
FDA Tue, 14 Apr 2009 00:00:00 -0400
FDA Warning Letter Issued to Amrex Zetron Inc on 14 Apr 2009 by Los Angeles District Office
WL Issued to Coast Institutional Review Board
FDA Tue, 14 Apr 2009 00:00:00 -0400
FDA Warning Letter Issued to Coast Institutional Review Board on 14 Apr 2009 by Center for Drug Evaluation and Research
WL Issued to Branitz, Bruce, MD
FDA Thu, 09 Apr 2009 00:00:00 -0400
FDA Warning Letter Issued to Branitz, Bruce, MD on 09 Apr 2009 by Center for Drug Evaluation and Research
WL Issued to Cote, Charles J., MD
FDA Mon, 02 Mar 2009 00:00:00 -0400
FDA Warning Letter Issued to Cote, Charles J., MD on 02 Mar 2009 by Center for Drug Evaluation and Research
WL Issued to Genzyme Corporation
FDA Fri, 27 Feb 2009 00:00:00 -0400
FDA Warning Letter Issued to Genzyme Corporation on 27 Feb 2009 by New England District Office
WL Issued to Hammill Manufacturing Company
FDA Tue, 06 Jan 2009 00:00:00 -0400
FDA Warning Letter Issued to Hammill Manufacturing Company on 06 Jan 2009 by Cincinnati District Office

CFDA: FDA Latest Drug GCP Warning Letters

WL Issued to Coast Institutional Review Board
FDA Tue, 14 Apr 2009 00:00:00 -0400
FDA Warning Letter Issued to Coast Institutional Review Board on 14 Apr 2009 by Center for Drug Evaluation and Research
WL Issued to Branitz, Bruce, MD
FDA Thu, 09 Apr 2009 00:00:00 -0400
FDA Warning Letter Issued to Branitz, Bruce, MD on 09 Apr 2009 by Center for Drug Evaluation and Research
WL Issued to Bukowski, Ronald M, MD
FDA Mon, 30 Mar 2009 00:00:00 -0400
FDA Warning Letter Issued to Bukowski, Ronald M, MD on 30 Mar 2009 by Center for Drug Evaluation and Research
WL Issued to Youabian, Inc
FDA Tue, 17 Mar 2009 00:00:00 -0400
FDA Warning Letter Issued to Youabian, Inc on 17 Mar 2009 by Los Angeles District Office
WL Issued to Provena St. Joseph's Medical Center IRB
FDA Thu, 12 Mar 2009 00:00:00 -0400
FDA Warning Letter Issued to Provena St. Joseph's Medical Center IRB on 12 Mar 2009 by Center for Biologics Evaluation and Research
WL Issued to Paulson, Daniel M., MD
FDA Wed, 11 Mar 2009 00:00:00 -0400
FDA Warning Letter Issued to Paulson, Daniel M., MD on 11 Mar 2009 by Center for Drug Evaluation and Research

Subscribe to Drugs_and_Medications RSS feed